# Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes

Source: https://onco.cc/trials/nct01106040/  
OnCo record `nct01106040` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Technetium-99m tilmanocept in Breast cancer and Melanoma, run by Navidea Biopharmaceuticals, completed.

## Summary

Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes is a phase 3 interventional study registered as NCT01106040 by Navidea Biopharmaceuticals, with 163 participants recorded, started 2010-06 and reaching its primary completion in 2011-04. Interventions recorded: Lymphoseek. Conditions recorded: Breast Cancer, Melanoma.

Linked to the drug Technetium-99m tilmanocept because the registry names it among its interventions and Breast cancer and Melanoma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT01106040
- Phase: 3
- Setting: A Phase 3, Prospective, Open-Label, Multicenter Comparison Study of Lymphoseek® and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Patients With Known Melanoma or Breast Cancer Who Are Undergoing Lymph Node Mapping
- Sponsor: Navidea Biopharmaceuticals
- Enrolled: 163

## Sources

- ClinicalTrials.gov NCT01106040: https://clinicaltrials.gov/study/NCT01106040

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Melanoma](https://onco.cc/cancers/melanoma/)
- drugs: [Technetium-99m tilmanocept](https://onco.cc/drugs/tilmanocept-tc99m/)
- companies: [Navidea Biopharmaceuticals](https://onco.cc/companies/navidea/)

---
JSON: https://onco.cc/api/v1/entities/nct01106040.json